DNA Manufacturing Market (2026 – 2033)

DNA Manufacturing Market Summary

The global DNA manufacturing market size was estimated at USD 6.4 billion in 2025 and is anticipated to reach USD 23.1 billion by 2033, growing at a CAGR of 17.8% from 2026 to 2033. This growth is driven by increasing demand for gene therapies, personalized medicine, and advancements in synthetic biology.

Expanding applications in pharmaceutical research and vaccine development also contribute to market expansion. For instance, in July 2024, GenScript Biotech announced the launch of an advanced DNA synthesis platform that reduces production time, enabling faster development of gene therapies and synthetic vaccines.

Growth of Gene Therapy

Gene therapies are transforming the treatment landscape for genetic disorders, rare diseases, and common chronic conditions. Gene therapies directly modify or replace faulty genes within a patient’s cells, offering the potential for long-lasting or curative effects. For instance, in September 2022, GenScript USA Inc. introduced the GenWand Double-Stranded DNA (dsDNA) service, designed to enhance CRISPR-based gene editing in T-cell engineering. This service offers covalently closed, linear DNA templates that are more stable and less prone to endonuclease degradation, thereby improving homology-directed repair (HDR) efficiency and reducing off-target effects compared to traditional PCR-based methods. This innovative approach requires large-scale production of highly precise, pure DNA sequences to develop therapeutic vectors, such as viral carriers or plasmids, that deliver corrective genes into patient cells.